Elevated serum soluble Fas ligand in natural killer cell proliferative disorders.
We evaluated the serum level of soluble Fas ligand (sFasL) in patients with natural killer lymphocyte proliferative disorders (NK- LPD). The serum sFasL level was elevated in neoplastic groups of aggressive NK leukaemia, indolent NK leukaemia and NK lymphoma, all of which contained clonal EBV-DNA. In NK leukaemia the serum sFasL level was significantly higher than that found in others. However, it was not elevated in the patients with reactive NK-LPD and in one patient with NK leukaemia in remission. These findings indicate that the serum sFasL level is a useful indicator in evaluating disease activity.
Kato
K
K
First Department of Pathology, School of Medicine, Fukuoka University, Japan.
Ohshima
K
K
Ishihara
S
S
Anzai
K
K
Suzumiya
J
J
Kikuchi
M
M
D000293:Adolescent; D000328:Adult; D000818:Animals; D009033:Culicidae; D004797:Enzyme-Linked Immunosorbent Assay; D053222:Fas Ligand Protein; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology; D007299:Insect Bites and Stings / Q000276:immunology; D007694:Killer Cells, Natural; D008232:Lymphoproliferative Disorders / Q000097:blood*; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins